Close Menu

licensing agreement

Oncore and its partners will commercialize GeneNews' ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement

ERS Genomics was founded to provide access to foundational CRISPR-Cas9 IP held by Emmanuelle Charpentier for applications other than human disease treatment.

Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.

Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.

The partners will offer Onegevity's GutBio assay, which integrates metagenomic sequencing with AI-based personalized recommendations to improve gut health, in Japan.

The San Francisco-based startup, which closed a $5 million Series A round in 2017, aims to develop nutritionally enhanced food and feed crops.

The agriculture company said it will use the technology it has licensed for new applications in crop editing and for research to bring new foods to market.

The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.

The biotech startup, which had been working with Cas12 and Cas13, has now licensed the recently discovered Cas14 protein from UC Berkeley.

CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.